Dronedarone is an amiodarone analogue (with fewer adverse side effects than amiodarone), which has been shown to reduce atrial fibrillation recurrence compared to placebo, but long term safety had not been established. In this large RCT of >4000 patients, patients on dronedarone had lower cardiac hospitalizations and death than those on placebo (after mean f/u of 21 months). There was no difference in the groups in pulmonary, liver, or thyroid toxicity, so this drug will likely replace some amiodarone in the management of patients with atrial fibrillation (abstract).
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]